REG - Silence Therapeutics - Director/PDMR Shareholding

Silence TherapeuticsAnnouncement

03/12/2020 09:45

RNS Number : 4344H
  
Silence Therapeutics PLC
  
03 December 2020
  
 

Director Dealing
3rd December 2020
 
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that, on the 30th November 2020 and 1st December 2020, 4,700 and 1,000 American Depositary Shares ("ADSs") respectively were purchased by Mark Rothera, Chief Executive Officer of the Company, at $18.20 per ADS. Each ADS is a tradeable security representing 3 of the Company's Ordinary Shares  
 
Following this purchase, Mark Rothera is interested in 5,700 ADSs representing 17,100 ordinary shares (0.02%) of the issued share capital of the Company.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
 



1.


Details of the person discharging managerial responsibilities (PDMR) / person closely associated




a)


Name


Mark Rothera
 




2.


Reason for the notification




a)


Position / status


Chief Executive Officer
 




b)


Initial notification / Amendment


Initial notification




3.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Silence Therapeutics plc
 




b)


LEI


213800SSURRJBX85SQ91
 




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


American Depositary Shares (ADS), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc
 
 
 
ISIN US82686Q1013




b)


Nature of the transaction


Purchase of Silence Therapeutics plc ADS
 




c)


Prices(a) and volume(s)


 



Price(s)


Volume(s)




$17.98


1200 ADSs




$17.99


500 ADSs




$18.99


800 ADSs




$18.35


200 ADSs




$18.00


2000 ADSs




$18.30


1000 ADSs



 
 




d)


Aggregated information
- Aggregated volume
- Price


Aggregate Volume: 5,700 ADSs
Metric for Quantity: ADSs
Aggregated Volume Price per ADS: $18.20
 




e)


Date of the transaction


30 November 2020 (Time zone: Eastern Standard Time)
1 December 2020 (Time zone: Eastern Standard Time)




f)


Place of the transaction


Nasdaq Capital Market
 



 
 
 
Enquiries:
 



Silence Therapeutics plc
 Gem Hopkins, Head of IR & Corporate Communications


Tel:  +1 (646) 637-3208




 
Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 


 
Tel:  +44 (0) 20 7597 5970




European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com 
 


Tel: +44 (0) 20 3709 5700




US IR
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
 


 Tel: +1 (443) 213-0505



 
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.  Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHGCBDDGSGDGGX